Chinook Therapeutics (Nasdaq:KDNY) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

KDNY Aperçu des actions

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases.

A propos de l'entreprise

KDNY analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	2/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 63.8% par an

Analyse des risques

Cours de l'action très volatil au cours des 3 derniers mois

Les actionnaires ont été dilués au cours de l'année écoulée

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Chinook Therapeutics, Inc. Concurrents

SpringWorks Therapeutics

NasdaqGS:SWTX

US$2.8b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

Janux Therapeutics

NasdaqGM:JANX

US$2.3b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Chinook Therapeutics
Historique des cours de bourse
Prix actuel de l'action	US$40.39
Plus haut sur 52 semaines	US$40.51
Plus bas sur 52 semaines	US$18.34
Bêta	0.67
1Variation sur 1 mois	2.98%
Variation sur 3 mois	72.68%
Variation sur 1 an	95.69%
3Variation sur 3 ans	n/a
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	173.46%

Nouvelles et mises à jour récentes

Recent updates

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

May 28

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

Feb 14

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Aug 31

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Aug 12

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Aug 08

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

Jul 05

Rendement pour les actionnaires

	KDNY	US Biotechs	US Marché
7D	0.3%	4.7%	3.1%
1Y	95.7%	15.1%	24.9%

Rendement vs Industrie: KDNY a dépassé le secteur US Biotechs qui a rapporté 15.7 % au cours de l'année écoulée.

Rendement vs marché: KDNY a dépassé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is KDNY's price volatile compared to industry and market?
KDNY volatility
KDNY Average Weekly Movement	17.1%
Biotechs Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Cours de l'action stable: Le cours de l'action de KDNY a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de KDNY est passée de 10% à 17% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
n/a	214	Eric Dobmeier	www.chinooktx.com

Chinook Therapeutics, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Chinook Therapeutics se comparent-ils à sa capitalisation boursière ?
KDNY statistiques fondamentales
Capitalisation boursière	US$2.90b
Bénéfices(TTM)	-US$245.65m
Recettes(TTM)	US$5.85m

495.8x

Ratio P/S

-11.8x

Ratio P/E

Le site KDNY est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
KDNY compte de résultat (TTM)
Recettes	US$5.85m
Coût des recettes	US$193.72m
Marge brute	-US$187.87m
Autres dépenses	US$57.79m
Les revenus	-US$245.65m

Derniers bénéfices déclarés

Jun 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-3.42
Marge brute	-3,211.95%
Marge bénéficiaire nette	-4,199.93%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de KDNY?

Voir les performances historiques et les comparaisons

KDNY Aperçu des actions

Récompenses

Analyse des risques

Chinook Therapeutics, Inc. Concurrents

NasdaqGS:SWTX

US$2.8b

NasdaqGS:TPTX

US$3.8b

NasdaqCM:CPRX

US$2.5b

NasdaqGM:JANX

US$2.3b

Historique des prix et performances

Nouvelles et mises à jour récentes

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Price target increased by 7.8% to US$39.45

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

New major risk - Share price stability

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

President recently sold US$190k worth of stock

Chief Scientific Officer exercised options and sold US$191k worth of stock

Chief Operating Officer exercised options and sold US$246k worth of stock

President exercised options and sold US$657k worth of stock

Consensus forecasts updated

Chief Operating Officer notifies of intention to sell stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Operating Officer exercised options and sold US$217k worth of stock

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Chief Operating Officer exercised options and sold US$145k worth of stock

Independent Director recently bought US$212k worth of stock

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Consensus revenue estimates fall by 14%

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chief Scientific Officer exercised options and sold US$98k worth of stock

Chief Scientific Officer exercised options and sold US$89k worth of stock

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

High number of new directors

President recently bought US$65k worth of stock

Consensus forecasts updated

Price target increased to US$34.86

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chief Scientific Officer exercised options and sold US$75k worth of stock

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

Chinook Therapeutics, Inc. Résumé des fondamentaux

495.8x